By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BioTime, Inc. 

1301 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-521-3390 Fax: 510-521-3389


Key Statistics

Ownership: Public

Web Site: BioTime
Symbol: BTX

Company News
BioTime (BTX) Receives DSMB Approval To Start Third Patient Cohort In Clinical Trial For Dry-AMD; Commences Patient Enrollment In The U.S. 7/26/2017 7:16:18 AM
BioTime (BTX) To Announce Second Quarter 2017 Results On August 2, 2017 7/20/2017 9:01:25 AM
Data From BioTime (BTX)’s Phase I/IIa Opregen Trial To Be Presented At The 2017 American Academy of Ophthalmology Annual Meeting 7/19/2017 6:44:07 AM
BioTime (BTX) To Host Key Opinion Leader Event On The Topic Of Dry AMD In New York City 7/18/2017 7:24:57 AM
BioTime (BTX) Subsidiary AgeX Therapeutics, Inc. Appoints Aubrey De Grey, Ph.D. As VP Of New Technology Discovery 7/13/2017 6:28:14 AM
Hadasit Bio-Holdings Ltd.  (HDST) And BioTime (BTX) Complete Shares Swap Transaction In Cell Cure Neurosciences Ltd. 6/20/2017 10:28:56 AM
BioTime (BTX) Expands & Advances Ophthalmology Portfolio 6/19/2017 9:07:33 AM
BioTime (BTX)’s Renevia Achieves Primary Endpoint In European Pivotal Trial 6/14/2017 6:54:28 AM
BioTime (BTX) To Announce Top Line Data From The Company’s Renevia European Pivotal Trial 6/9/2017 6:33:16 AM
BioTime (BTX) Co-CEO Dr. Michael West To Deliver Presentation As Part Of Biotech Panel At Mauldin Economics' Strategic Investment Conference On May 24 5/24/2017 8:44:13 AM